Patent intelligence · US
US 8822698
Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family
Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family
Patent details — US 8822698
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 2, 2014
- Expiration
- Aug 28, 2034
- Claims
- 19
- CPC classes
- A61P, A61P25/04, A61P29/00, A61P31/00
Quick answer
US 8822698 (Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family) is held by Oreste Piccolo Studio di Consulenza Scientifica. Status: granted. Granted Sep 2, 2014. Expires Aug 28, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61P, A61P25/04, A61P29/00, A61P31/00, A61P35/00, A61P35/02
More from Oreste Piccolo Studio di Consulenza Scientifica
Related pharmaceutical patents in our USPTO index.
-
US 12414942
Compositions, methods, and systems for treating presbyopia
granted -
US 12180206
Aceclidine derivatives, compositions thereof and methods of use thereof
granted -
US 12128036
Compositions and methods for storage stable ophthalmic drugs
granted -
US 11648247
Compositions and methods for the treatment of presbyopia
granted -
US 11344538
Methods for the treatment of myopia
granted -
US 11273150
Compositions and methods for the treatment of presbyopia
granted -
US 11214569
Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
granted -
US 11179328
Compositions and methods for the treatment of presbyopia
granted
Frequently asked questions
What is US patent 8822698?
US 8822698 (Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family) is held by Oreste Piccolo Studio di Consulenza Scientifica. Status: granted. Granted Sep 2, 2014. Expires Aug 28, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8822698?
Oreste Piccolo Studio di Consulenza Scientifica is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 8822698 expire?
Our index shows an expiration date of Aug 28, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.